Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378898 · ClinicalTrials.gov registry record · NA
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT00378898: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT00378898 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00378898, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal esophagus. There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH monitor compared with a distal monitor.
Interventions
- PROCEDURE Fluoroscopy
- DEVICE BRAVO capsule
- OTHER sham BRAVO capsule placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-07 |
| Phase | NA |
What the finished NCT00378898 record still lists
NCT00378898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Fluoroscopy is the first listed.
NCT00378898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00378898 about?
NCT00378898 is a clinical study titled "Feasibility of Placing Bravo PH Capsule in Proximal Esophagus". Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal esophagus. There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH monitor compared with a distal monitor.
What is the current status of trial NCT00378898?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2006-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00378898?
The interventions under investigation include: Fluoroscopy (PROCEDURE), BRAVO capsule (DEVICE), sham BRAVO capsule placement (OTHER).
Who is sponsoring clinical trial NCT00378898?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00378898's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia